Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
GSK878 is a highly potent HIV-1 inhibitor that exerts its antiviral effects through the selective targeting of viral replication mechanisms. With an EC50 value of 39 pM, it demonstrates strong efficacy in suppressing HIV-1 activity. This compound is utilized in research for its potential applications in the development of long-acting therapeutic strategies for HIV treatment. -
HIV Inhibitor
HIV-IN-8 is an effective HIV inhibitor that targets the replication process of the virus. With an EC50 value of 13 μg/mL, this compound demonstrates a significant capacity to inhibit HIV replication in vitro. It is suitable for research applications focused on understanding HIV biology and evaluating antiviral strategies. -
HIV-1 IN Inhibitor
Hyrtiosal is a potent inhibitor of the N-terminal domain (NTD) of HIV-1 integrase (HIV-1 IN), exhibiting an IC50 value of 9.60-0.86 μM. By specifically binding to the Ser17, Trp19, and Lys34 residues on the NTD, Hyrtiosal effectively disrupts the interaction between HIV-1 viral DNA and integrase, thus hindering the formation of the pre-integrated complex essential for viral replication. This compound is valuable for research focused on discovering and developing novel anti-HIV therapeutics. -
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV Protease Inhibitor
BMS 186318 is a potent HIV protease inhibitor that plays a critical role in blocking viral replication by interfering with the proteolytic processing of viral polyproteins. This compound demonstrates enhanced anti-HIV efficacy when used in conjunction with reverse transcriptase inhibitors and additional protease inhibitors. BMS 186318 is ideal for applications in antiviral research, contributing to the development of effective therapeutic strategies against HIV. -
HIV-1 integrase Inhibitor
MK-0536 is a potent inhibitor of HIV-1 integrase, demonstrating significant efficacy in suppressing the replication of wild-type viruses. This compound retains antiviral activity against several drug-resistant mutants, including Y143R and N155H, while exhibiting no cytotoxic effects on uninfected cells. MK-0536 operates by selectively blocking the strand transfer reaction of integrase through magnesium ion chelation at the active site, as well as interactions with viral DNA and integrase residues. This reagent is valuable for investigating the mechanisms underlying HIV infection and resistance. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
Non-Nucleoside Reverse Transcriptase Inhibitor
DPC 961 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. It exerts its biological activity by non-competitively inhibiting the enzymatic function of reverse transcriptase, effectively blocking viral replication. This compound is primarily utilized in research focused on AIDS and the mechanisms of HIV pathogenesis. -
Non-nucleoside Reverse Transcriptase Inhibitor
DPC 963 is an oral active non-nucleoside reverse transcriptase inhibitor that demonstrates an IC50 of 18 nM. This compound is primarily utilized in the study of HIV, providing insights into reverse transcription processes and potential therapeutic strategies. Its potent inhibitory activity makes DPC 963 a valuable tool for research in antiviral drug development and HIV pathogenesis. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies. -
HIV Attachment Inhibitor
BMS-663749 is an HIV attachment inhibitor that functions as a phosphonooxymethyl prodrug of BMS-488043. This compound effectively interferes with the binding of the HIV virus to host cells, thereby preventing viral entry and infection. BMS-663749 is primarily utilized in research focused on HIV biochemistry and therapeutic development strategies targeting viral attachment processes. -
HIV-1 Inhibitor
A-75925 is a selective inhibitor of the HIV-1 protease, a key enzyme in the viral replication process. By interfering with the protease activity, A-75925 effectively inhibits HIV-1 replication, making it a valuable tool in HIV research. This compound can be employed to investigate antiviral strategies and the mechanisms underlying HIV resistance. -
HIV-1 Inhibitor
N.41 is an HIV-1 inhibitor that functions by disrupting the interaction between the viral Vif protein and the host antiviral factor APOBEC3G (A3G). By protecting A3G from Vif-mediated degradation, N.41 increases cellular levels of A3G and enhances its incorporation into viral particles, resulting in reduced HIV-1 infectivity. This compound demonstrates significant antiviral activity against HIV-1 replication in peripheral blood mononuclear cells (PBMCs), with an IC50 value of 8.4 μM, highlighting its potential for research applications in HIV-1 studies and antiviral drug development. -
HIV-1 Inhibitor
NBD-10007 is a CD4 agonist that specifically targets HIV-1. It demonstrates significant anti-HIV-1 viral activity, making it a valuable reagent for studying HIV pathogenesis and testing potential therapeutic interventions. Its unique mechanism of action may provide insights into CD4 receptor modulation and immune responses in HIV infection research. -
HIV-1 Inhibitor
BMS 488043 is an orally active inhibitor that targets the attachment process of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes. It exhibits strong antiviral activity by preventing viral entry, making it a valuable tool for research into HIV-1 transmission and infection dynamics. This compound is suitable for studies focusing on the development of therapeutic strategies against HIV-1. -
HIV-1 Inhibitor
Methyl salvionolate A is a potent inhibitor of HIV-1 that targets multiple viral enzymes. It demonstrates significant activity by inhibiting the production of P24 antigen in HIV-1 infected MT-4 cells with an EC50 value of 1.62 μg/ml. Additionally, Methyl salvionolate A effectively inhibits HIV-1 reverse transcriptase, protease, and integrase, with corresponding IC50 values of 50.58, 10.73, and 7.58 μg/ml, respectively. This compound is valuable for research into HIV-1 antiviral strategies and the development of therapeutic agents. -
HIV Nef Inhibitor
DLC27-14 is an HIV Nef inhibitor with an IC50 value of 15.92 μM, effectively disrupting the function of the Nef protein in HIV-1. This compound is valuable for research focused on HIV pathogenesis and exploring therapeutic strategies targeting viral replication. Its mechanism of action provides insights into the role of Nef in HIV dynamics and potential avenues for antiviral drug development. -
HIV-1 Inhibitor
TNK-651 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively blocking viral replication. It demonstrates inhibitory activity against both the HIV-1 SF33 strain and the NNRTI-resistant HIV-1 A17 strain. TNK-651 is valuable for research applications focusing on HIV-1 infection and resistance mechanisms. -
HIV Inhibitor
12-Methoxydodecanoic acid is an HIV inhibitor that exhibits anti-viral activity with an IC50 of 6.8 μM. This compound, a heteroatom-containing analog of myristic acid, has also been shown to inhibit the moloney murine leukemia virus (MoMLV). Its unique properties make it suitable for research into viral inhibition mechanisms and therapeutic development in HIV-related studies. -
HIV Inhibitor
GSK163929 is an orally bioavailable CCR5 antagonist, primarily targeting HIV infection. This compound demonstrates anti-HIV activity by inhibiting the CCR5 co-receptor, crucial for viral entry into host cells. GSK163929 has been evaluated for safety, showing no adverse effects in rat and dog models at specified dosages. Its properties make it a valuable tool for research in HIV therapies and co-receptor interaction studies. -
HIV-1 RT Inhibitor
L-697639 is a potent inhibitor of HIV-1 reverse transcriptase (HIV-1 RT), exhibiting an IC50 range of 20-400 nM in a template-primer-dependent manner. This compound demonstrates significant antiviral activity, effectively inhibiting up to 95% of HIV-1 infection in human T lymphocyte cultures at concentrations between 12-200 nM. L-697639 is a valuable tool for research applications focused on HIV-1 therapy and the mechanisms of viral replication. -
HIV gp120 Inhibitor
Chloropeptin I is an inhibitor of the HIV glycoprotein 120 (gp120), blocking its binding to the CD4 receptor with an IC50 of 2.0 μM. This compound exhibits selective anti-HIV activity, making it a valuable tool for research into HIV transmission and infection mechanisms. It serves as an important reagent for studying potential therapeutic strategies targeting HIV entry into host cells. -
HIV-1 Inhibitor
HIV-1-IN-86 is an HIV-1 inhibitor that targets viral replication. With an EC50 value of 0.77 μM, this compound exhibits significant antiviral activity against HIV-1. It is a valuable tool for research applications aimed at understanding HIV-1 biology and developing antiviral therapies. -
HIV-1 Protease Inhibitor
SDZ283-910 is a potent inhibitor of HIV-1 protease, targeting a crucial enzyme in the viral replication cycle. By disrupting the proteolytic processing of viral proteins, SDZ283-910 exhibits significant antiviral activity against HIV-1. This compound is valuable for research applications focused on understanding HIV biology and developing antiviral therapies. -
HIV-1 Inhibitor
HIV-1-IN-82 is a small-molecule entry inhibitor targeting HIV-1 with an IC50 value of 0.39 μM. This compound demonstrates potent antiviral activity, making it a valuable tool for research focused on anti-HIV-1 infection. It is suitable for studies investigating mechanisms of viral entry and the development of novel therapeutic strategies against HIV-1. -
HIV Inhibitor
GSK-364735 sodium is a potent inhibitor of the integrase enzyme of human immunodeficiency virus type 1 (HIV-1), demonstrating an IC50 value of 7.8 nM. As an antiretroviral agent, it serves as a valuable tool for studying HIV-1 replication and therapeutics. This compound is essential for researchers investigating integrase inhibition and its implications in HIV treatment strategies. -
HIV Integrase Inhibitor
PF-4776548 is a potent inhibitor of HIV integrase, a crucial enzyme in the integration of viral DNA into the host cell genome. By blocking this integration process, PF-4776548 demonstrates significant potential in the study of HIV replication and the mechanisms of AIDS pathogenesis. This compound is valuable for research applications aimed at developing antiviral strategies and understanding HIV-related diseases. -
HIV Inhibitor
Scirpusin A is a naturally derived compound from the legume Caragana rosea Turcz, recognized for its anti-HIV properties. It exhibits substantial inhibitory activity against HIV-1, with an effective concentration (EC50) of 7 μg/mL. Scirpusin A serves as a valuable tool in the research and development of novel anti-HIV therapeutics, contributing to the understanding of potential treatment options. -
HIV-1 Protease Inhibitor
LY-326188 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 0.42 nM. It effectively protects HIV-1 infected cells from viral replication. This compound is valuable for research aimed at understanding HIV biology and developing antiviral therapeutics. -
HIV Inhibitor
KRH-3955 is a potent CXCR4 antagonist that demonstrates significant anti-HIV-1 activity, particularly against X4 strains. It effectively inhibits the replication of various X4 HIV-1 clinical isolates and is active against recombinant strains with resistance mutations in reverse transcriptase, protease, and tyrosinase. KRH-3955 disrupts the binding of SDF-1alpha to CXCR4, thereby interfering with calcium signaling through this receptor, along with inhibiting antibody binding to CXCR4. With an oral bioavailability of 25.6% in rats, KRH-3955 has shown efficacy in vivo, making it a valuable tool for HIV research. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-15 is a selective inhibitor of HIV-1 protease, exhibiting a pIC50 value of 9.347. This compound effectively inhibits the maturation of HIV proteins, thereby blocking viral replication. It serves as a valuable tool for research on HIV-1 infection and potential therapeutic interventions. -
HIV-1 RT Inhibitor
7-Deaza-2',3'-dideoxyguanosine is an inhibitor of HIV-1 reverse transcriptase, functioning as a 2′,3′-dideoxynucleoside 5′-triphosphate. It demonstrates potent antiviral activity with an inhibition constant (Ki) of 25 nM, making it a valuable tool for research into HIV replication and reverse transcription processes. This compound is particularly useful for studies aimed at understanding the mechanisms of HIV resistance and the development of antiviral therapies. -
HIV Protease Inhibitor
MK-8718 is a potent and orally bioavailable HIV protease inhibitor that features a morpholine aspartate binding group. This compound effectively inhibits the activity of HIV protease, making it a valuable tool for studying HIV infection and antiretroviral therapy mechanisms. Its application in research may enhance the understanding of HIV replication and contribute to the development of novel therapeutic strategies. -
HIV Protease Inhibitor
PAC-Phe-Val is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 33.10 nM. It establishes stable interactions with key active site residues, which enhances its inhibitory efficacy. This compound is suitable for research applications focused on HIV/AIDS and provides significant potential for therapeutic development in this area. -
HIV-1 Inhibitor
Hinokinin is a compound derived from the stems of Hypoestes aristata, primarily targeting the HIV-1 protease enzyme. It demonstrates moderate inhibitory activity against HIV-1, making it a potential candidate for antiviral research. This compound can be utilized in studies aimed at understanding the mechanisms of HIV-1 replication and developing therapeutic strategies against HIV infection. -
HIV protease inhibitor
Brecanavir is a potent inhibitor of HIV protease, a crucial enzyme in the HIV life cycle. By inhibiting this enzyme, Brecanavir effectively reduces viral replication, making it a valuable compound in HIV research and therapeutic development. Its potential applications include studying drug resistance mechanisms and exploring combination therapies for enhanced antiviral efficacy. -
Anti-HIV Nucleoside Reverse Transcriptase Inhibitor
CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research. -
HIV-1 Protease Inhibitor
TMC310911 is a potent and orally bioavailable inhibitor of the HIV-1 protease. It exhibits significant antiviral activity, with EC50 values ranging from 2.2 nM to 14.2 nM against wild-type HIV-1. Additionally, TMC310911 demonstrates effective activity against a broad range of recombinant HIV-1 isolates, making it a valuable tool for research on HIV-1 infection and resistance development. -
HIV Protease Inhibitor
Isoescin IA is a triterpenoid saponin derived from the seeds of Aesculus chinensis, functioning as an HIV protease inhibitor. This compound exhibits significant anti-HIV-1 protease activity, making it a valuable tool for research aimed at understanding HIV replication and potential therapeutic strategies. Its selective inhibition of the protease can aid in the investigation of antiviral mechanisms and drug development in the field of HIV research. -
HIV Protease Inhibitor
Ganodermanondiol is an HIV protease inhibitor derived from Ganoderma lucidum. It demonstrates significant anti-HIV-1 protease activity, with an IC50 of 90 μM, making it a valuable compound for antiviral research. Additionally, Ganodermanondiol exhibits strong cytoprotective effects against tert-butyl hydroperoxide-induced hepatotoxicity and showcases anticomplement activity against the classical pathway of the complement system, with an IC50 of 41.7 μM. This compound is relevant for studies focused on hepatoprotection and immune modulation. -
HIV-1 Protease Inhibitor
SKF107457 is a potent inhibitor of HIV-1 protease, a key enzyme critically involved in the viral replication process. This compound exhibits significant antiviral activity against HIV-1, making it valuable for studying the mechanisms of HIV infection and resistance. Additionally, SKF107457 can be utilized in research focused on developing new therapeutic strategies for AIDS. -
HIV-1p Inhibitor
NIT is an HIV-1 protease (HIV-1p) inhibitor, exhibiting Ki values of 96 μM for wild-type HIV-1p and 91 μM for multidrug-resistant HIV-1p. This compound demonstrates significant potential for studying HIV protease activity and developing therapeutic strategies against HIV infection. Its application in research may further elucidate mechanisms of viral resistance and aid in the design of more effective antiretroviral agents. -
HIV Protease Inhibitor
HIV-IN-11 is a potent HIV protease inhibitor that disrupts the activity of HIV-1 protease through competitive inhibition, with a Ki of 0.049 nM. This compound effectively inhibits the replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. Demonstrating a longer half-life compared to indinavir sulfate in animal models, HIV-IN-11 represents a promising candidate for second-generation HIV treatment research. -
HIV-1 Inhibitor
Mvt-101 is a hexapeptide-based inhibitor targeting HIV-1 protease. This compound functions as a reduced-peptide-bond inhibitor, effectively blocking protease activity and thereby inhibiting the replication of the HIV virus. Mvt-101 is particularly relevant for research in virology and therapeutics aimed at tackling HIV infection. -
HIV Protease Inhibitor
DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, targeting both HIV-1 and HIV-2. It functions as a competitive inhibitor by blocking the cleavage of peptide substrates and the HIV-1 gag polyprotein, demonstrating robust antiviral activity. DMP 323 exhibits comparable efficacy to leading HIV protease inhibitors while remaining effective in human plasma or serum, indicating low affinity for plasma proteins. Additionally, it shows minimal inhibition of mammalian proteases at higher concentrations, underscoring its selectivity for HIV protease. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-9 is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.028 nM. This compound demonstrates significant antiviral activity, with an IC50 of 66.8 nM, making it a valuable tool for research in HIV treatment and drug development. Its efficacy highlights its potential application in studies aiming to inhibit HIV replication and investigate resistance mechanisms. -
HIV-1 Protease Inhibitor
L-687908 is a highly potent HIV-1 protease inhibitor with a competitive inhibition constant (CIC95) of 12 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. Its key biological activity makes it a valuable tool for antiviral research and the development of therapeutic agents targeting HIV-1. -
HIV Protease Inhibitor
AQ148 is a selective HIV-1 protease inhibitor with a Ki value of 137 nM. It demonstrates significant inhibitory activity against aspartic proteases from HIV-1 (IC50 = 1.5 μM), HIV-2 (IC50 = 3.4 μM), and simian immunodeficiency virus (SIV) (IC50 = 5 μM). This compound is useful for research applications focused on HIV pathogenesis and the development of antiviral therapies. -
HIV Protease Inhibitor
20(21)-Dehydrolucidenic acid A is a triterpenoid derived from the fruiting body of Ganoderma sinense, primarily targeting HIV protease. This compound exhibits modest inhibitory activity against HIV-1 protease, making it a valuable tool in the study of HIV pathogenesis and in the development of antiviral strategies. Its unique structure offers potential insights into therapeutic applications for HIV treatment. -
HIV Protease Inhibitor
U-85548E is an HIV protease inhibitor that demonstrates nanomolar affinity for the HIV-1 aspartic protease. This compound has been developed through investigations into its structure-activity relationships, proving effective against both HIV-1 and HIV-2 proteases. Its binding interactions have been characterized using X-ray crystallography and molecular modeling, making it a valuable tool for research in HIV drug development and mechanistic studies of protease inhibition.
